<SEC-DOCUMENT>0000950170-25-090160.txt : 20250626
<SEC-HEADER>0000950170-25-090160.hdr.sgml : 20250626
<ACCEPTANCE-DATETIME>20250626063004
ACCESSION NUMBER:		0000950170-25-090160
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250626
FILED AS OF DATE:		20250626
DATE AS OF CHANGE:		20250626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		251075020

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 400, 2440 RESEARCH BLVD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(301) 670 2800

	MAIL ADDRESS:	
		STREET 1:		SUITE 400, 2440 RESEARCH BLVD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>pr_-_esmo_abstract_pr_-_.htm
<DESCRIPTION>6-K
<TEXT>
<html>
 <head>
  <title>6-K</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM 6-K</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF FOREIGN PRIVATE ISSUER</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE SECURITIES EXCHANGE ACT OF 1934</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the month of June 2025</font></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: 001-39173</font></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I-MAB</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2440 Research Boulevard, Suite 400</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rockville, MD 20850</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form 20-F &#9746;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;Form 40-F &#9744;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:90%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibit No.</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="imab-ex99_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">99.1</font></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="imab-ex99_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release - I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025</font></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:5%;box-sizing:content-box;"></td>
     <td style="width:2%;box-sizing:content-box;"></td>
     <td style="width:43%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I-MAB</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joseph Skelton</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joseph Skelton</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: June 26, 2025</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>imab-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44095488_0.jpg" alt="img44095488_0.jpg" style="width:199px;height:72px;"></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">83% ORR (10/12) in patients across doses selected for ongoing dose expansion study</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Responses observed in patients with low PD-L1 and/or CLDN18.2 expression</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Updated results to be presented at ESMO GI on July 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">nd</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Company to host investor event on July 8</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">th</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ROCKVILLE, MD, June 26, 2025 (Globe Newswire) &#x2013; I-Mab (NASDAQ: IMAB) (the &#x201c;Company&#x201d;), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">ESMO Gastrointestinal Cancers Congress 2025 (ESMO GI 2025)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> abstract #388MO related to positive data from a Phase 1b  study evaluating givastomig in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers. An objective response rate (ORR) of 71% (12/17) was observed across all dose levels with an ORR of 83% (10/12) observed at dose levels selected for the ongoing dose expansion study (8 and 12 mg/kg). Responses were rapid and deepened over time, and were observed in tumors with low levels of PD-L1 expression and/or low levels of Claudin 18.2 (CLDN18.2) expression. There was a favorable safety profile, with low incidence of GI and liver toxicities. I-Mab intends to host a virtual investor event on Tuesday, July 8</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (register </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">here</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) to recap the data being presented at ESMO GI.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The abstract is based on the results of the dose escalation part of a Phase 1b study (NCT04900818) evaluating the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of givastomig used in combination with nivolumab and mFOLFOX6 as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (&#x2265;1+ intensity in &#x2265;1% of cells). The primary endpoint is safety. The study only enrolled patients in the U.S.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We are excited to share positive initial data from the Phase 1b dose escalation study of givastomig in gastric cancers at ESMO GI 2025. Givastomig shows promising activity in the first line setting, with responses that are both rapid onset and durable, deepening over time. This is the first study to evaluate givastomig in combination with immunochemotherapy and we are very pleased by the overall tolerability, consistent pharmacokinetic data and soluble 4-1BB induction. We look forward to sharing the data with the oncology and investment communities at ESMO GI 2025 on July 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">,&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Givastomig's strong response data and favorable safety profile are encouraging. I look forward to presenting the data for this novel Claudin 18.2 targeted therapy next week at ESMO GI and discussing with colleagues,&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> &#x201c;Gastroesophageal cancers continue to be a significant unmet medical need, and novel combination approaches are critical. On behalf of the study team, I am enthusiastic to continue to support the givastomig clinical program.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ESMO GI Presentation Details:</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Speaker: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Samuel J. Klempner, MD, Associate Professor of Medicine, Massachusetts General Hospital</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Presentation Number: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">388MO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Date and Time: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Wednesday, July 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> at 16:50 CEST (10:50am EST)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">17 advanced metastatic gastric cancer patients were treated with givastomig across the 5 mg/kg (n=5), 8 mg/kg (n=6), and 12 mg/kg (n=6) dose levels as of the February 28, 2025, data cutoff. All patients were efficacy evaluable</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Patient Characteristics:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The 17 patients enrolled in the study were treatment na&iuml;ve metastatic gastric, esophageal or gastroesophageal adenocarcinomas</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Patients were HER2-negative, Claudin 18.2-positive (defined as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&gt;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1+ intensity in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&gt;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1% of tumor cells) regardless of PD-L1 expression levels</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">All patients were enrolled at sites within the United States</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Efficacy Results:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Objective Response Rates (ORRs):</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">71% of patients (12/17) achieved a partial response (PR) per RECIST v1.1</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.999615998463994%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5 mg/kg (2/5)</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.999615998463994%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">8 mg/kg (5/6)</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.999615998463994%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12 mg/kg (5/6), with one unconfirmed response as of the data cutoff</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">At the doses selected for dose expansion (8 and 12 mg/kg), 83% (10/12) of patients achieved PRs</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">80% of patients (4/5) with CLDN18.2 expression below 75% (CLDN-Low) achieved a PR. The CLDN-Low response rate increased to 100% of patients (3/3) in the doses selected for expansion (8 and 12 mg/kg)</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The disease control rate (DCR) was 100% across the three dose levels</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Dose-dependent PK was observed, similar to monotherapy PK.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Patients also experienced a dose dependent induction of soluble 4-1BB, a positive indicator of T cell activation and engagement</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.32%;box-sizing:content-box;"></td>
     <td style="width:33.34%;box-sizing:content-box;"></td>
     <td style="width:33.34%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ORR: % (n)</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">All</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(n=17)</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cohorts Chosen for expansion</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(8 and 12 mg/kg)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(n=12)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">PD-L1</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Any</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">71 (12/17)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">83 (10/12)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2265;5</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">82 (9/11)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">89 (8/9)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&lt;5</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">50 (3/6)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">67 (2/3)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2265;1</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">73 (11/15)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">82 (9/11)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&lt;1</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">50 (1/2)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">100 (1/1)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CLDN18.2</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2265;75</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">67 (8/12)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">78 (7/9)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&lt;75</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">80 (4/5)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">100 (3/3)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Durability:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">8 of 17 patients remained on study treatment and the longest treatment duration was 11.3 months as of the data cutoff </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Safety:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">No dose limiting toxicities (DLT) were observed and a maximum tolerated dose (MTD) was not reached</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Common treatment related adverse events (TRAEs, &#x2265;10% of patients) were generally Grade 1 or Grade 2 including nausea, vomiting, infusion related reaction, fatigue, decreased appetite, diarrhea, abdominal pain, chills, dyspepsia and gastritis</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Grade 3 TRAEs attributed to givastomig were rare, with single cases of abdominal pain, ALT/AST increases, gastritis, and infusion related reaction</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">No Grade 4 or Grade 5 TRAEs were reported</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Virtual Investor Event:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Register for the Post-ESMO GI 2025 Investor Event </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">here</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. A replay of the webinar will be accessible on the News &amp; Events page of the I-Mab website for 90 days.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Givastomig</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#0432ff;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About I-Mab</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company&#x2019;s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.</font></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.i-mabbiopharma.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> and follow us on LinkedIn and X.</font></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">I-Mab Forward Looking Statements</font></p><p style="font-size:10pt;margin-top:9.6pt;font-family:Times New Roman;margin-bottom:9.6pt;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This announcement contains forward-looking statements. These statements are made under the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">safe harbor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">will</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">expects</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">believes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">designed to</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">anticipates</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">future</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">intends</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">potential</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">estimates</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">confident</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s pipeline and clinical development of I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s drug candidates, including givastomig; the projected advancement of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s portfolio and anticipated milestones and related timing; the Company&#x2019;s expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s drug candidates; I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s ability to achieve commercial success for its drug candidates, if approved; I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s limited operating history and I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Risk Factors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> section in I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#262626;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">s subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.</font></p><p style="font-size:10pt;margin-top:2.4000000000000004pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">I-Mab Investor &amp; Media Contacts</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">PJ Kelleher</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">LifeSci Advisors</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">+1-617-430-7579</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">pkelleher@lifesciadvisors.com</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IR@imabbio.com</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img44095488_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44095488_0.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "F <D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **\-^.G[1GPH_9V\-GQ%\2O$<5A)/'(VC>';$)>^)O$,T9"F'2-)61)'
MC$C+'/J%T]KI=HSH+R^@+H&_#GXF?\%:OCEKGB>>X^&6D>&_ WA* M%8:;J&
MFV_B36+U!(V+K5]1OHQ )I8PA6VTRSLHK4,\+S7S*MT?TG@KPGXTX[ISQ639
M?3P^6PYDLUS2I/!Y?5J0=G1PU14JU;%5%*\9O#4*M.E)<M>I2;2?X]XC>.OA
MUX85J>"XAS6KB<WJ<DGD>2T:>89I1HS2:KXNDZ]##X*FXRC.G'&8FA6KP?-A
MJ5:,9./]'%%?SE^$?^"O7Q[TJ=1XN\&_#OQ98@KO6VL=7\/ZFX'W@M]:ZM=6
M$1;H&.BRA>NQL8/WS\'O^"JGP ^($]KI7CRTUKX2ZS<&.,7&L$:[X4,S@_(-
M?TVWAO+5002]QJ>AV%C"I#2WH 8CU,^\#/$K(*-3$U,B_M3#4DY3K9)B*68R
M22NVL'3<,QDDKMRC@W%)-MI'B<+_ $F?!WBFO3PE+BA9+C*THQIX?B/"5\HA
M*4G91>855/*8R<FHJ,LPC*4FE&+/TA\2>)- \'Z#J_BCQ3K&G^'_  [H-A<:
MGK.M:K=166G:;86L9DN+J[N9F6.**-!U)W,Q5$#.RJ?YI/VVO^"LGCOXC7>K
M?#O]FN_U+P#\/4-QI]_X_A$MAXY\7)DQ/+I,XVW/@_1I0&:V^R^7XBN8_*FN
MKW3!+<:0F#_P4F_;<O?VA/%ES\)_AKK,@^"GA#4"D]W83,L'Q$\164A5];N)
M(R!=>'M.G5D\-VQ+6]QM.OR^;/<Z?'I?Y02:<.?EQCC/Y]P3CGVS7^9_BWX[
M5\;C\7PSPAC98;*\)4GALPSC"U.3$9G7A)0K4<%7BU*C@(24H.M2E&IC6G*%
M3ZI)*OY_B%XAXS'5:^2\.XJ6&R^FY4<7F.'FXU\=->[.GAJT'S4L)%WBZE)J
M>)LVIK#NU7B;6]UK2-176-*U74M-U:.1IDU2POKFTU!)F;>TJ7EO+'.LA?#;
MQ(&+<DY%>NZ#^UA^U-X-E$WAS]H7XRZ=Y9&+=?B-XMGL3MZ*UA=:K-9.O'W'
MMV5AU&"*X*XL, _+_+M^A[G')Z9Q7/75G@'CWZ?Y/X=<8(Z5^)95Q%C<-*,L
M)CL5AI-J5\/B:M!WLE>]*<6GM9W_ $/PE2QN";EA,5B<+*_-S8:O5H2OI[RE
M2E%\RUUO?3>RL??7@'_@L'^W%\/Y(EU/QSX=^)-A"ZG^S_'WA#2+G=$&7<C:
MIX;C\-:](64%5DGU:9D9MS!\8/Z1?!?_ (+W?#O5I[32_C[\(==\%2R.L4WB
MKX?:A'XIT56*C-S=^'=5_LO6-.M4?=O6RU3Q'=;"IC@D((K^;J]M.N1T!_R/
M\X/3C@5QM];8W9''?T'H/?'\CTSFOV#AWQ0XPR^5-0SS$XRDK7H9E+^T(2CI
M:+GB?:5X+2W[FM3:Z-7L>O@/$KCO(I1>&S_%XRE%J^'S5K,Z4XJUH.6+]IB*
M<=$K4*]&=KV<;L_T$/@E^TQ\!OVC-'.M?!?XH>%?'<,4237VG:;??9_$6DK(
M%*C6O"^HI9^(=')WA4;4=,MHY3DPO(OS5[I7^<1\/_B#XJ^$GCGP[\0?!FLZ
MKH.O>&]1BO;>^T>^NM.O?)SY=Y;QW5I)%-&+JT:6!B'!.X'J!7]47[-/_!4?
M6K:UT32_C9;-XM\,ZC:V<UAX^T>&&+Q%9VEW'"]M-J^GQ"*RURW2&0--/;_8
MM414DDD.KW3B(_JM#Z17#>58[*LOXVP]3(*6;QG3PO$%)2Q&21QE*4%4P^8)
M<V*RQ2C5HSHUYK%85Q=:>(KX6G0E.7[_ , >,.$XHIUL-G>%I95F.&G3C4JX
M>=2I@:T*J]RLH5.:MAHN:G"493Q$*:49SKQ4TE^ZM%<OX-\;>$_B%X>L/%?@
MK7].\2>']20M::GIDXFA++CS;>="%FM+RW)"75C=Q07EK)F*X@BD!4=17]"8
M;$X;&8>AB\'B*&*PN)I4Z^&Q.&JTZ^'Q%"K%3I5J%:E*=.K2J0:G3J4Y2A.+
M4HMIIG[5"<*D8SIRC.$XJ4)PDI1E%JZE&46U*+6J:;36J"BBBMR@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OSP_;3_;S\*_LW6%UX,\'
M?8/%?QCO;7]SI;OY^C^#8[F(/;ZGXG\B1'EO'C=+BP\/Q2PW$\1CN[^:SM);
M,:A'^WI^VK8?LX>&#X+\$W5K>_&3Q3I[2:='B*YB\%Z/<>9"/$FI0.'C>_F9
M)$T#3[A&BEFBDU&]CEL[6*SU/^8S6-8U7Q#JNH:WK>H7FJZOJMY<7^I:E?W$
MMW>WM[=RO/<W-S<SO)-///-(\LLLKM))(S.[,S$G^F?!7P47$\:'%?%E"<>'
MXSYLLRR7-3GG4Z<K/$8AIQJ4\KA).,8P<9XZ<96E##1;Q'\:?2-^D>^"I8G@
M;@7$4Y\5RI\F<YS'DK4N'(58*2PN%B^:G5SJI3FIRE.,J66TY1;A4QDU'"])
M\0OB-XU^*OBK4_&GC_Q%J/B;Q)JT@>[U'49O,<(I;R;6VB4);V=E;*QCM+&T
MB@L[2+]U;011 (.)HHK^XJ%"AA:-+#8:C2P^'H4X4J%"A3A1HT:5.*C3I4J5
M-1A3IPBE&$(148Q2222L?YHXG%8G&XBOC,9B*^+Q>*JU*^)Q6)JU*^(Q%>K)
MSJUJ]>K*=6K5J3;G4J5)2G.3<I-MMA52\9C$8D.&ERI/<)_%WX)^Z#Z$GM5N
MEB@,S[B,CH/I]/?\SD^O'\1_M /&S$^#O@)F>&R7&2P?%?B-C'P7DU>C4=/%
M8'+\3AJN(XFS6A*+C.$\/E$)Y;1Q%*4:V$Q^<8#$TFITXGZ?X/<*PXFXNHU,
M5253+\EIK,\3":O3JUH5(PP.'FG=-3Q#5>4))QJ4<-6A+23,)=/.,A<9Z\#K
M4,UA@'Y><]<#K_\ 6YSGTKODT[(SSSGH/KCH1[8_7BJES8[0>/\ )]>/_K<?
M6O\ FLAFWOVYMGM=*R]U6T].C[']ORP5HWY;:+U>W]/??[_,+NRP#QZ]O\_G
MV/L:Y.^M,9./7/'Y_B.,CIG]/4KVV !X]?T_GCMZ<C-<9?P@;@1Z^AZ?XC/7
M/3)Z5];EF.<G%W?3>_2VFS[K].M_$QF'2OI_6FNBV[[KUZ>87UOC=QZ_YS_A
MDXKBM1@ W''KUX]?_K^_([#->EW\6-WMD$\<8[#T_E_*N(U"/AL>^,\Y_P .
M0/Y]J_2<IQ#?)J^G_MOSVT=^WH?)8VDES*ROKV6UGUW5K=[[NVAYK?1?>X]?
M?GV'4GIS^M?<G[-_B1M9\ '2)Y"]UX5U"73 &.7_ +.N@;[3B0>=L8EN+5.P
M2V50!C%?%.H)C=ZY(';V'YU[;^S%K!LO&^MZ&6Q%K>A-<*I(P;K1[E)4('=C
M:W=WT[+R.,B?$K+(YOP)F4E'FKY5*AFN'=KN/U>:IXIWWY?J5?$2?1RBFUHK
M'"6+>!XCPD+VIXV-3!5%?=U$IT5KI?ZQ"DEULVMWK^L_P#_:/^)'[//B:/6_
M!>J-)I5S/"?$'A2_>6;0?$%K&0K17=J'7R;M(RPL]2MC%>V;G]W*T$EQ;S_T
MA?L__M$> ?VB?"">)?!]W]FU.S6"+Q+X6O)8SK'AV^E5B([A5"?:M/N&24Z=
MJL,:V]XD<B.EM>P7=E;?R@5ZE\'OB_XT^"/CC2O'7@C47LM1T^0)=VCEGT_6
M--D=#>:1JMJ'1;JPO$15EC+))'(D-U:RV][;6MU!\5X&_2 SWPKS"AE69U,3
MF_ N*KI8W*93=6OE+JS_ 'F8Y(ZDDJ-2#E*KB<!S1PN.]^ZHXJ4<3'^GN&^*
M,3DM6-"LYU\MG+]Y0;O*A=ZU</=^ZUJYTKJ%37X9M37]<U%>*? +XZ>$/V@O
MA[IWCGPK*L,QVV7B+099DEO_  WKL<2/<Z;=X5#)$P=;C3[WRHTOK*2*;RX9
MO/MH/:Z_UDRC-\MS[*\!G63XRAF&5YGA:6,P.-P\^>CB,/6BITYQ>C3L^6<)
MJ-2E-2IU(PJ0E%?N%"O1Q-&EB*%2-6C6A&I3J1=XRA)7375=FG9IW32::"BB
MBO1-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXC_P""A7[;7@/]@+]E
M_P =_'_QD+74]8L(/^$?^&?@R:Y-O<>/?B5J]O<GPUX;B*'STL%:VN=9\17D
M :73O#.E:O?0I-<PP6\WVY7^<G_P7Y_;WNOVP?VQ-7^&/@S6GO/@?^S/>:S\
M._"$-G<L^F>)/'4=S';_ !(\<;8V,%U]JUBPC\,Z)=*\]O)H'ARSU*Q>+^V[
MU9?O_#?A!\8\1T<)7C)97@HK&YK.+<7+#PFE#"QFK<M3&57&DFFIPH^WK0NZ
M-C\^\2N,H\&<-UL91E%YIC9/!933DE*V)G%N>*E!W4J>#I<U9J2<)UO849V5
M:Y]NW'Q8\8?'2/3OB_X^U0ZSXO\ B+HVB>+=>OPIB@>_UK2+*]EALK??(MGI
MUIYHM--L(F,%A806]G;A8((U6M7A?[,FLC7?V??A%?E]\D?@K3-+G/'%QH1E
MT293@##*^GD$=<]:]TK_ $WP,*-+!8.EAZ=.C0IX7#PH4:4(TZ5*C"C"-.G3
MIQ2C"G""C&$(I1C%)))*Q_BGG4L1/.,VGBZM6OBIYECI8FO6G*K6K5Y8JJZU
M6K4FW.I4J5'*<ZDFY3E)R;;;84445U'F",<*3Z G_/7^5:FG $J3U]S]?_K\
M_P"%8ET_EPLV<9*KV[L,]>.F?Z8/(LV5UMVG.2,=_P ?\XP/J,U_@S^UDXHQ
M&9>*?AUP93JRE@^&>!*^>.DI>[',>*\\QF%Q*E';F^H\,99)-IM1J.UDS^N/
MH\8&&'R#.<SE%*KCLVCA>:VKH9?A:52%O^XN.KWMV[GHULL7EC<>,=?7/K^F
M1BLK4%0;L8Q@Y_+C(]SCL/TJE#J&%X8K^/K[^O3W'UJE=7P<'YNOZ_YP.![<
M@ 5_D=1PE:->]V]5ITZ6MU6CMKIOT/Z2J5Z;IJ-E=K37IIV_X=ZZ7L8%^!AL
M8SS^'4#Z5P^H!?FYY_K@]/U]:ZN^N <G/KZ9_/H?Q[]ZXO4)0=W..O3/N.GK
MC)]<=*^]RBE-<B>KT?K;E6N^FCMZ:V/FL;*.JT>EOR^=M-UW.+U+^+/O_(X_
M6N'U+^+\:[+4),[L]#D^XS^?''2N(U"3AN_7^O7]*_4LHB[0]$O2_+9_Y_(^
M.QTEKVLU?TM]YP]_U?Z'^8KH_@S?G3_BSX.<-M6[U"ZTZ3MN6_TZ[ME0^H,K
MQD#^\!CG%<QJ##+$'N?;/7^8&:F^'DI3XE^!&0\_\)7HJCMQ)?1QM^A.1W'!
MXK[7'8=8CAW/</-7C6R/-*,D^G/@*T;N^FG-=>A\[AZKI9MEM2.DJ>98*:ZZ
MPQ-'3Y[?,_4^BBBOX2/Z./J+]DW]HS6/V=/B=8Z\KSW7@S7'M])\<Z)&S,M]
MH[2G;?VT6=AU;19)'O=-=@K.?M.GM-!:ZC>,?ZA-'U?3/$&DZ9KNBWUOJ6CZ
MS86FJ:7J-I();:^T^_@CN;.[@D'#Q7$$L<L;<$JPR <BOXV:_<__ ()@_'Z3
MQ#X;UCX%>([XRZGX4BFU_P %27$A:6?P[<7(_MC2%=V)8Z3J-U'?VD>YY&M=
M2O(XTCM-,0+_ &Y]$'Q:K93G4O##.L3*64YY.MBN&9UIMQR_.HQE6Q.7P<G:
MGALVI0J5J5--1CF5%1I0=;,JLG^B\!YY*AB'D^(G^XQ+E/!N3TI8BW-.DKZ*
M%>*<E';VT?=7-6DW^M-%%%?Z2'ZV%%%% !1110!_(9^V'_P7 _;0^!7[4?QY
M^#W@JP^#,OA/X;_$_P 6^$?#TFM>!M8O=6;2-%U:YLK(ZA>0^+[2*YN_(B3S
MYX[:!))-SK#&"$'S;_Q$,?M[_P#0-^ W_AO-=_\ FWKX+_X*4_\ )_'[7'_9
M=_B'_P"I#>5\05_7^4\&<*5LJRNM5R#+*E6KEV!JU9RPT'*=2IA:,YSD^LI2
M;DWU;?=G\:YQQOQ;0S?-:-'B'-*=*CF6.I4J<<3-1A3IXJK&$(KI&,8J*6R2
ML?ZH'AZ^GU30-#U*YV"YU'1],OK@1*4C\^[LH+B7RT+,53S)&V*68JN 6)&3
ML5S?@W_D4/"O_8MZ'_Z:[6NDK^0ZB2G-+1*<DEV2;/['I-NG3;=VX0;?=N*;
M?WA1114%A7X.?\%C_P#@H]^T+^PEXJ^!FC_!*V^'UQ9_$7P_XVU/7_\ A-O#
M=_KLJW/A_4?#]K8?8)++7='%O&8M3N?/219S(PC(9-I!_>.OY(_^#EW_ )'_
M /90_P"Q/^*7_IZ\'5]QX<X#!YGQ=EN#S##4<7A:M/'.I0KP52E-T\!B*D'*
M+T?+.,91[22?0^#\2\PQV5\'9GC<NQ5;!XNE5RY4\10FX58*IF.%IU%&2U2G
M3G*$N\9-=3Y6_P"(AC]O?_H&_ ;_ ,-YKO\ \V]'_$0Q^WO_ - WX#?^&\UW
M_P";>OPLJ:>WN+63RKF"6WE,<,HCFC>)S%<1)/!(%<*WES021S1/C;)%(DB$
MJP)_I;_4CA#_ *)[*O\ PEATM_P+^OGK_,'^O?&7_11YM_X53^7Y?/7S/]%/
M_@F7^UKKO[:/[)7@[XR>,H]#M_B FO>+/"/CZT\.6LUCHUMK^A:O)+8_8K*X
MN[Z>U2[\*ZCX<U&6&2[F*SWDI1A&55?O^OY2O^#;#XT[+S]HO]GF_NE N+7P
MY\8/#%F9,'S+25?!_C698SPS2QWG@5?DRVRV<L-JY']6M?R[QQE%/(^*<WP%
M&DJ.&5=8G"4XJT(8;&4X8FG3IK^2C[5T%V]DUT/ZMX$SFIGO"F3YA7JNMBGA
MWAL94D[SGB<'.6&J5*C_ )ZWLU7D^OM;[,\B^/WQ4L/@=\#_ (M_&'4O):U^
M&GP[\7>-!!.6$=Y=:!HE[J&GZ=A2KL^IW\-MI\2(0\DMRB*0S U_&P?^#A?]
MO;)VZ;\!RN3M)^'FN9(SQG_BMNN*_<S_ (+Z_&C_ (5I^PI?>!;*[:#6?CCX
M_P#"_@A8X6"W!\/Z'-)XXU^X'?[,9?#FD:1=X&&CUI8F($O/\+X!)  )). !
MR23T '<FOU3PKX1RG,<BQ>9YOEN%QTL3CY4<)]:I*K[/#X6G",IT^;2*J5ZE
M6$[;NA&^UC\E\6>,<XRW/L'E>39GBL!'"X"-;%K"U73=3$8JI*4(5.767LZ%
M*E.%]E7E9:N_[I_\1#'[>_\ T#?@-_X;S7?_ )MZ_0'_ ()C?\%?OVL?VN_V
MO? OP/\ BK9_"B#P7XAT/QSJ6HOX5\'ZKI&M>?X=\'ZSK>GBWO[KQ1J<,2&^
ML;?[0&LY#+!YD2F-G$B?R87%O/:SS6MS#+;W-M+)!<03(T4T$\+F.6&6-P'C
MDC=61T8!E8%6 ((K]@_^"$?_ "D?^%'_ &*?Q6_]5QXDK['B?A#A?"\-Y[BL
M-D66T<1A\HS"M0K4\/",Z=6GA:DZ=2$EM*,HJ49+9JY\5PKQGQ7B^)L@PF*S
M[,ZV'Q&<9=0Q%"KB)RA5I5,72A4ISB]XSBW&2>Z;75G]Z%%%%?R<?UZ,DDCA
MC>65TBBB1I)))&5(XXT4L[N[$*B(H+,S$*J@DD 5_&E\<O\ @X,_:JT_XQ?$
MS3?@SIWP<?X4Z9XT\0Z9\/KG7?!NL:KJ^H>%-.U*>RT;5=0OH?%EC%-<ZM9P
M1:G(L=I"D)N_(52L08_T#?\ !6S]I ?LT?L-_%WQ#IVH?8/&7Q#L!\(? K1R
MK%=C6_'EM=V6J7UF^=\=UHGA"#Q+KEK.BGRKW3K495I$-?YZ1))))R222?4G
MDFOW+PGX0R[-,'F6;YQ@*&-H2K0P.!I8FFJE-2HQ5;%5E&6C;=2A2A-;<M:-
M]6C\&\7>,<RRG&Y7E&2X^O@:\:-3'8^KA:CIU'&K+V6$HRE'5)*G7JS@]U.A
M*UK7_=+_ (B&/V]_^@;\!O\ PWFN_P#S;U_43_P31_:^O?VV/V4O"/Q?\1IH
MMK\0K/6/$'@SXDZ9H$,EKI=AXJT*\$\#V=G/=WL]I;ZKX9U'P]K:02W,WDOJ
M,L"R.L.:_P Z.OZ/?^#=+]H__A#_ (Z?$S]FO6[\QZ/\7_#*^,/"$$TJB)?'
M7@&.XFO[.SB)!$^M^#;S5KV\D7=YB>$K*,@$*:^F\0N!\FAPQC,;DV583!8S
M+94\;*6%HJG.KA:=X8JG)QWA"C4>)=UH\.K-7=_E_#CCS.ZG%."P.=9MC,=@
M\RA4P,(8NLZD*6+J*,\)4@GJJE2K2CAE9Z_6'=-V:_L;HHHK^9S^H3\T_P#@
MJW^UE\4_V,?V6HOC'\'XO"T_BUOB7X3\)M'XOTBZUK23I6M:=XCNKPBSM-3T
MJ470ETNU\F;[441/-4Q,75D_FF_XB&/V]_\ H&_ ;_PWFN__ #;U^WW_  <'
M?\F!P_\ 9<?AY_Z9O&E?PW5_17A?PUD&:\,?6\RRC XW$_VEC*7ML10C4J>S
MA##.$.9Z\L7*32\WW/YL\5>)^(<HXI6$RS.,?@<-_9N#J^PP]>5.G[2<ZZG/
ME6G-)1BF^MD?NG_Q$,?M[_\ 0-^ W_AO-=_^;>C_ (B&/V]_^@;\!O\ PWFN
M_P#S;U^>_P"S#^P'^U-^V)HGBCQ%^S]\.[;QKI'@W4['1_$-S/XP\%^&C9:A
MJ5K->6<"P^*?$&C3W0EMX)',EI'/%'M"R.K,JGZ?_P"''G_!2G_H@VG_ /AU
MOA%_\W-?68G*O#'!5ZF%QE'A3"XFDXJKA\37P-&M3<HPG%5*52K&<'*,X22E
M%7C)/9W?R.%S?Q3QM"GBL'7XMQ>&K)NEB,-0QU>A549.$G3JTZ,H32G&46XR
M=I1E%ZW1]%:)_P '%G[;UA<(^L>!OV=]=M@P+P/X,\;Z?(Z]U$]E\2(PAQG#
M>4V"<D-C!^[_ -G_ /X.0? ^NZO8Z)^TG\#K_P "6-U+'#-XZ^&>LS>*=,L3
M)PUSJ'@W5[:SUF&PA/SS2:7KNO:AY>?L^EW,N(V_GX_:%_X)R_MG?LM^'&\9
M_&CX&^(O#O@R.:"WN?%VE:CX=\8^'=.FNI!#;)K&J>#=8UZWT,7,[1V]M)K+
M6$5U<RQ6UN\L\B1GXCIO@;@#/,+*I@L!E]2C-RA'&Y/BVE":2OR5,-6GAW.%
MTW"I3J13:YX-.Q*X]\0\AQ<:6.S#,:5:FHSG@LXP<6ZE-O3GIXJA#$*G/E:5
M2E.G)V?+4339_J0_#CXD^ _B]X)\/_$?X9>*]&\;>!_%5BFHZ#XDT&Z6[T^_
MMF9HW ;"RVUU;3I+:W]A=Q6]_IU[#/97]M;W<$T*=O7\8'_!OO\ M<>)_ /[
M1-W^RMKFKSW7PX^-6FZYJWAG2;J9G@\/_$OPMHMQKOV_30Y*VL7B+POH^JZ;
MJ\,0!O[VQ\.2$K]A(D_L_K^<>,.&JO"F=ULLE5=>A*G#%8+$22C*KA*LIQ@Z
MD59*K3J4ZM&IRVC*=-SBHQDDOZ8X,XHI<6Y'1S2-)8>O&I/"X[#Q;E"CBZ,8
M2FJ<G[SI5*=2E6I\UY1C44).4H2D_P V_P#@K5^UM)^QA^PA\;/BSHU^+#X@
M:QHZ?#/X4R)(([E/B'X_2?1]+U2RRRA[GPII?]M>-5C.1+'X:DC((>O\P"SL
MY;F9YYV:6::1I)9'8N[R.Q=V=F)9F9B6)8DDG)))S7];_P#P=/\ Q^FU;X@?
MLU?LM:7?9L?#'AS7/C=XOL8G9EFU?Q/?77@WP2;A0VQ+C2M,\/\ C*6)67>8
M/$8?(5US_*QI6GY"\>_3J#_^O]:_J7P1X?CE?"%/,IPMB\^Q%3&U)->^L)0G
M+#8*#[P2C6Q,-_\ >Y/3I_)OCQQ++,N,*N6PJ7PO#^'IX*G%.\7BZ\*>*QM5
M*^DN:I1PM31+_9%KO?\ 7K]@WQ$-1^#5YX:D?-SX/\4ZC;JA.673]=2/5[1@
M,D[#=OJ:*<;<QD \8K[9K\I_V*O$X\,_$6\\-W$GEV/C;26LXE) 0:SI!DO]
M-/)&'FMSJ5L",EWGB7'*X_5BOZ@RBJJF!HKK17L7Z0MR?^4W#\5T/X&XTPGU
M7B'&S2M3QDHXRF^[K+]\_7ZQ&M\K.VH4445Z1\J,DBCE4+(@=0P8!NFX9P?U
M/YT+&B8VHJX]% Z?A^GKSUI]?1'[-/[-OCK]IGXA6O@OPC#]DTZV$5[XK\4W
M4,DFE^%]%,NR2]NMA3[1>7!5X-*TR.6.?4KL%%>"UAO;VS^%XFX4\-JD\;Q;
MQ=PIP7B\1A,%%8WB#/.',EQ^.IX'"\SI49YAB\#7QDZ5)SE'#8:-25ZE7V="
MDZE51E]'P^N*LUQV X<X;KYSB,9F.+CA\!E678O%05?%5VDW"C3JPHPNH\]:
MO/DITJ4)5:U2%*G.<<#X&? 7XE_M#>-+?P7\.-%DU"ZQ'/J^K7!>WT+P[IS2
M;&U/7-1$<D=E:@AA&BI+=WLBFVL+6[NV2W?]_P#X=_\ !+#]FSP_X&M="^(&
MFZM\0/%TJQ3ZMXN&NZ[X=$=V(\/;Z)I>DZG!:6^FQ,28UU--4N[A@9+B?RS'
M:P?9OP-^!7P]_9[\"V/@3X>:2EG9PB.?5]6N%CDUKQ+JHC$<VKZW>HB-<W4N
M"L,*A+2PM]EI8P6]M&D8]CK_ #M\7,?X?>(6+J8#+O#/@/+^'</5?U>4N#.&
MXYMF$H-J.*Q6,CEWUC#4Y:RI8+#5HP@I7Q$\144'3_U/\&/ 7#\!Y7''<79A
MB>*.*L=ATL73Q>-Q6,R/*85$G/!9?@J]1T,36B_=K9GB:,JTY)K"0PM*515O
MQQ^(_P#P1M^$.NQW4_PX^)?C7P7?2JS06OB&TTKQ?H\4@!VI'':Q^&=3CC8D
M*SS:A>NH (5CG=^8WQO_ ."5'[5GPTBO-2\-:%I7Q;T& O)]J\ WC7&MI;A"
MP:?PMJ<.GZU/<$KM-MH=OK84X_?%26']8]%?R_G7T?O#7-5.>#RFKP_BI7:Q
M&2XFI1IIZ<J>!Q+Q.!4$TKQHX>C)JZ52+LU^F9OX8\*YI"?L\+6RRM).U;+Z
MTH).VE\/6]MAG&]KJ%*G)K3G6Y_GR^)]+UGP[J5YH_B#2=2T/5K"9K>^TO5K
M*YT[4+&X4 M;W=G>1Q7-K,@9=\4T:NN?F5:\VU&;[W/K[?RXX./R_&O[X/CO
M^RQ\!_VDM'DTGXN?#W1?$-R(&@L/$D,/]F>+]'!&4;2_$UAY.J01QN%D^PRS
MSZ9.R*+NQN(P4/\ -?\ MG_\$<?BY\'+;5O'GP#NM0^,OP[M$N+V\\.QV@'Q
M-\.642;V9]*L8Q;^+[6% Y>[\/PP:F<EF\-Q6\4MW7XUGW@CQ#PNYXK+YPS_
M "RG>3K86E.ECZ$%9N6(P'-5<HI;U,-5Q&B<ZD*,-%_/_&OA-Q)D5*MC<O7]
MNY=34IU*F$I2CCL/36KE6P'-4G.$5:\\+4KVBI5*D*,$?AQ?R]<'IG'J/Z$?
MX_A5_P"&,9N_BGX"@7D_\)/ILIQUVVTIN7/X+"Q)[#]>>U0RVTLT%Q&\,\+O
M'-%*K1R12(2KHZ,%960@A@0"",$ UZ%^SK8-JOQ@T*3&8]'L]9U:0]E\K3Y;
M*'/H?M%]#@^O3O7Q&<R67\*<1XN:Y5A\AS6<;_S_ %"LJ4>C3E4<4EW:LMC\
M-R^+Q.=Y3AXZNIF>!B[=%]9I.;?E%)M]K;,_3*BBBOX'/Z4"O6/@;\3=1^#W
MQ7\$?$336E+>'=<M9[ZWB)#7^CW!:RUK3<;E4_VCI-S>V09\B)IQ* 61:\GH
MKMRW,,9E&8X#-<OK2PV/RS&X7,,#B(:3H8O!UX8C#5H[>]3K4X37=JVQI1JU
M*%6E7I2<:M&I"K3DMXU*<E.$EYJ23^1_95IFI66L:;I^KZ;<1W>G:K8VFI:?
M=Q'=%=65]!'=6MQ$W\4<T$L<B'NK U>KXL_X)_\ Q$;X@_LS^#4N9Q/J7@BX
MO_ M^0^XI%HS0W.BQ8)+*L'AW4=(MAG@F!MO K[3K_<_@[B+#\7<*<.\3X9*
M-'/LFR[-%3B[^PJ8S"TZU;#-[\V&K2J4)]ITY(_I' 8N..P6$QD-(XK#TJW+
M_*ZD%*4'?K"3<7YIA1117TAUA1110!_G#?\ !2G_ )/X_:X_[+O\0_\ U(;R
MOB"OM_\ X*4_\G\?M<?]EW^(?_J0WE?$%?W+DG_(ER?_ +%67?\ J'1/X,SW
M_D>9S_V-<Q_]2ZQ_J:>#?^10\*_]BWH?_IKM:Z2N;\&_\BAX5_[%O0__ $UV
MM?%GQ!_X*@?L'?"KQMXH^'/Q _:(\.^'/&O@S6;WP_XGT&X\->/[N?2=9TZ9
MK>]L9;G3O"5Y8S26\R-&[VMU/"6!V2,.:_BG#Y?C\QKUJ>7X'&8ZI3<ISIX/
M#5L3.$'/E4YQH0G*,>9J/,TES-*]VC^XZ^8Y?EN'P]3,<?@\!3J*%.G4QN*H
M86%2?L^;DA*O.G&4^5.7+%MV3=K(^]Z*_-?_ (? ?\$WO^CHO"__ (2/Q,_^
M8FC_ (? ?\$WO^CHO"__ (2/Q,_^8FNW_5GB3_HG\\_\-./_ /F?S7WG#_K3
MPQ_T4>0_^'?+_P#YH\U]Y^E%?R1_\'+O_(__ +*'_8G_ !2_]/7@ZOZ>?@;^
MT!\'OVE/!+?$;X'^-['Q_P""DUF^\/MKVGV&LZ= NLZ9#9W%]8FVUW3=*OA)
M;PW]G(S_ &7R76=?+D<A@O\ ,-_P<N_\C_\ LH?]B?\ %+_T]>#J^L\,J%;#
M<>9=0Q%&KAZ]*&90JT:U.=*K2FLNQ5X5*<U&<)+K&44UU1\AXIUZ&)\/\SQ&
M&K4L10K5,JJ4J]"I"K1JPEFF#<9TZE-RA.#6JE&33Z,_F#K[R_;A^#D?P^T_
M]DGXC:=:&+1OCE^R%\$O%LMRJE8'\5^%_#,'P^\36R\!3<;/#&D:Q=%2<OKB
MNWS.<_!M?TC_ +=_P='CK_@B_P#L ?'&QM%FU+X-:3I'AO5;H)\]MX1\>Q7.
MBW,DDH!/EQ>*?#'A.RA1SM5]2?;AF(/]&9UF/]G9IPUS2Y:68YE7RJIK9.6*
MP5:KAE9Z-RQ>&P\%U]YVWU_FK(\M_M+*N*.2/-6R[+,-FM)=HX7'T*6)?I'!
MXG$3?^%'YT_\$@OC4/@A_P % /@+JUW>+::'X[UVX^$WB#>_EQ3VGQ&M7\/:
M0D\A*JD-KXLN/#FIN7.P?8%+#C(_T)Z_RO= UK4O#>N:-XAT>[DL-6T+5+#6
M-+OH21+9ZAIMU%>6=U$001);W$,<J$$$,@((K_3K^!/Q0TWXV?!7X4?%[26C
M-A\2OAYX1\:QQQG*VLGB+0[+4[JQ;NLNGW=Q/93H<&.:WDC;!4U^.^->6<F,
MR;.(1TQ&'K9?7:6BGAJGUB@Y/K*I#$UHKKRT;:I:?M/@;FGM,#G633EKAL31
MS&A%O5PQ5/ZO74>JC3GAJ,FMN:O?JS^3+_@XY^-'_"4?M%?"#X(6-TTFG_"G
MX=77B?5H4D'EQ>*/B3J2226\\08YFM_#?ACPW=Q.Z@K%JKA"0[5^/_["/P8/
M[07[8/[//PFDM?MFF>)OB;X=F\26^PR"3PAX>N?^$F\8Y'0%?"VCZNRESL#!
M=V1P=/\ X*#?&<_'_P#;0_:+^*,-R;O2]9^)6N:3X;N/,\Q)?"?A%X_"'A2:
M+#,J)/X=T+3)]J87?(QQN))_6+_@W-^"O_"4_M'_ !8^.>H6K2:9\(/AS'H&
ME7$D>(X?%?Q(O9;6&XAF9<&6#PMX>\5VDZ(P*1ZI&7&'7/Z)'_C#_#=/^%B,
M#D5^SCF>/C=+HVUF.+2[V78_-Y+_ %S\36E^]P^.SZS=^92RO+I6;6Z2>78-
MO^5-]>OX-?%ZY2]^*_Q+O(T6-+OQ[XNN41 %1%GU^_E54"\!5#84#@ #%?J)
M_P $(_\ E(_\*/\ L4_BM_ZKCQ)7Y.>,[G[9XN\47><_:?$&L7&?7SK^XDS^
M.[-?K'_P0C_Y2/\ PH_[%/XK?^JX\25[?%4>7@_/X_RY!F$?NP-1'@\)2YN,
M^'I?S<0Y=+MOCZ3VZ;G]Z%%%<IX[\:>'_AOX(\8?$+Q9>IIWA?P-X8UWQ=XA
MOY"H6ST7PYIEUJ^IW!W%03%9VDS*N078!!RPK^,(0E4G&G"+G.<HPA&*O*4I
M-*,8I:MMM));MG]NSG"G"=2I)0A",ISG)I1C"*<I2DWHE%)MMZ)*Y_(%_P '
M%'[2/_";_'[X>?LW:'J/FZ'\%_#7_"2^++:"53$_C_Q_!:WL%K>1J3OET7P;
M;:%<6;L0T)\3:G#M!9\_SW>%/#>K^,O%'ASPAH%H^H:[XIUW2?#NBV$>?,OM
M6UJ_M]-TZSCP"?,N;RYAA0 $EG  )XKOOC[\7O$'Q]^-7Q0^,_BAW;6_B3XV
M\0>+;J%Y!*NGQ:MJ,]Q8Z1;N !]BT:P:VTJP0<1V5G!&ORH*_0[_ ((F_ C_
M (7;^WW\,;V^LS=^'/@W::K\9-=W0F2%+CPHMO:^$<NP,:2IXZU;PS=*C'=)
M#:W&Q3L8K_9. H4."^#81FHVR;*:F)Q'\M;&JG/$5TGI=5\9.4*=];3A'L?Q
M5F&(K\;\;3G!S_X6LWI8;#W7O4<"ZD,-0;6R]A@X1G4T2O"<GNSS_P#X*J?L
M>Z=^QA^TU9_#SPU;/%X)\0?"WX<>*/#5QB1H[JY@\/6_A/QC<&:3.^XOO''A
MGQ'K,L.=UO#JMJA 0QD_'_[.'QFUO]GGX\?"?XV>'C(VI?#;QQH'B?[-$XC.
MIZ?8WT1UG19'. MOKFCO?:/=\C=:WTRD@,37]:__  <%?LL^*?C-\(?@E\4_
MAMX/USQEX\\ ^/[CP'=:+X6TB_UK7M2\-_$:U22T:+3M,M[J\OAIOB;P]IMI
M:PQQ,T3^)+EUX=\_D]^SA_P;_?M;_%JTLO$'QCUCPO\ LZ^&;I$G-GXBSXL\
M?FV8[O-/A'0[R#3]/+1 EK?7O%&C:E;,0+C358,@\'A[C/),3P9@L7Q'F>$H
MRGAZ^79A#$U.:OB9T.:A4:P\.?$5W7PTJ56JZ=*>M9N5CZ'B/@G/,+QOCL+P
MUE>+JPIXC#YGE]3#T^7#X6-;EQ%.^(J<F'H1H8J-6E2]K4A_!5KV/[5_"?BC
M1/&_A;PUXT\,WT6I^'/%V@:/XGT#4H2##?Z+KVGV^J:7>Q$$@QW5C=03+R?E
M<5T%?''[/&B^!/V1O@%\./@/J/Q=NOB=_P *QT:3PU8>([G3[2+5;K3H[^\N
MM+TN:ST>:\T_3X-#L+FWT338+G4#-%IEA9)<7$TRO,^[K'[46E(7C\-^&+[4
MY Q4-J%TEF0 >91!9P:BLB8Y ^U1,>A*=:_B;B+Q X#X>Q>+HU^)\OJTZ&(K
M4Z*PSJXS%5*4*DHTIU,)@Z=?$4)U*:C-TZU*G*+E:2C9G]34,;;"X:>-4,/B
MYX>C/$X:$XUO88B5.,JU%2HN<9JG4<H*<6XR2YDVG<^"_P#@N]X&\:_$+]AR
MW\.^ ?!_BGQQX@?XT^ KM=#\(>']6\2ZN;2WTCQ@L]T--T:TO;S[-"TL22S^
M3Y4;RQ([AI$#?QEM^R+^U<JEV_9C_:$5 ,EV^#'Q'"@>I8^&PH'N2![U_>[J
M'[0?QQU@[O"'@O3)X"=JBRT+5]7NSN.%),&I7"#G'S&TV]<CH1RM[XX_;BOP
M9-$\,RP!AE(I_#6C6>.#C_D-64)';[TG7J<5T</?3#R/A#*GE64<!\=\6TEB
MZ^)6)R7AO&8ES=:-*/+"G*K1E9>S33:N^;96/R[B_@3+^+,V>;5,?F="2PM'
M"JEA<OA7A:BZC4^:=:$FY.KK'E5DEO<_/3_@W>^'?Q ^'/PE_:.T[X@^!O&'
M@74+WXA^#+BSL?&'AK6O#5W=P1^'=5CDFMK?6;*REGCC<JDCQ(PC9D#E2ZY_
MHJK\MW\9?\%);.420^ M+U2+D^5=P_#Z-2!G&1::U838/3 =6Z<C)-=!8_'[
M]NCP]'YGB[]FK3O$,<>2T?ARWU.&]F !.T2Z9K7BB%6.,;H]/DY.1&>!7Y]G
M7TH,BXASW&YMFWAOXR\,0QM2E*=7,?#/B+$8.BJ6'HT.9U\KHYC4E"U/G<E1
M]V[6MDW]CPW3PW#F2X')E#,ZM/ 0JP6)K9=5@ZBJ8BK7<G"BZR7*ZO+HW=1O
MHW8^K/VJ;KP%9?LT?'RY^*#::OP_3X0_$%?%8U9H%LI=)E\+ZG%-!_I'R-=W
M+O';Z=&F;F749+2*S5KMX5/^9*^-[[<;=S8QTQDXQ[8Z>U?W#?M:ZC\ ?VR?
M"</@3]KCP)^U/^S\+%"+#6/#VN^*(O!MG?I)YL&H:GX2O[6/PYXAN;2XVR0W
MMW\/M2U2.%3;V>J6RD$?A3\4?^"(OQXFUS3KW]DSQSX"_:E^'.M:M#IZZSHN
MO:)X*\6>#$NS+)%)\0?"OB;5[<:3;V\"H)+O3]1U&XF;,DNE:>98+=_ZG\ ?
M&+PFS>AF&6Y;QWELL\QLZ>*J9)F:JY+CL/0PM.HO:+ 9HL-CH<RJ-U9XK"X5
M^Y"G&,W!M_D7BKA,TXFQ^ JY/@*>/PV74:M%K!5)5LTG/$U*4G]8RR=&CC:=
M*FX)4W2I8BE'FJ3G5ASJ*\;_ ."+O@S6_&/_  4<_9^DTB"62W\)77C'QCKU
MS&&*:?HND>!O$43SSLH.R*ZU*]TW259B%:XU*"(G,@4_Z!5?DM_P2T_X)B:!
M^P-X-UGQ+XMU73/&?[0'Q!T^UL?&'B32XYCH/A;0(9H[U/!/A&6[AM[VYLGO
MXX;[7M:N;:REUR\L]-5;"UM=*MO._6FI\2>(\'Q)Q%[?+Y>UP6!PE/ 4<1RN
M*Q+IU:]>K6@I)25-U*\J=-R2<X4U4LE.R_2?#'AK&\,\-^PS&/LL=C\94S"O
MA^92>&52C0H4J$W%N+JJGAXU*BBVH3J.FVW!M_YL/_!;3XE3_%G_ (*@?M-W
MS7!GT[P1X@\/_"[2(]Q9;.'X?>%=%\/ZK;("2$#>)[?7KN11A?.NIB1N)S^<
MFD60^7Y>F#TZGCZ=!C/X\>GK7[4OBE/B%^U?^TMXZCO$U&#Q?\??B_XDM;V-
M_,BN;+6/'_B"_LY87_BA>UGB,1_BCVGD<5QNC6H.SCT)_P#K_P">ISP>*_N#
MAC 1R_(<DP"CR+!Y3EV&M;K1PE&F[]G*47*5TG=NZ/X$XPS*68\09[CY3<GC
M<WS+%7O?2MC*M2*7]U1DE%K:-EHD=OX4DO-%U/3-8TYS#J&EWMIJ-G,,@QW%
MG,D\+9 S@NBAP.&0LI!!Q7[0^$_$EGXO\-Z-XDL=H@U:QBN6B#!C;7.-EY9O
MCH]I=)- P/)\L-T(-?CYH]IG;\O7'KP ?P_#\/K7VU^SIXQ.D7,W@[4)MMAJ
MTWVC2'D;"6VJ[0LUL,C")J4:J4 *K]KA0<M<DU][E57V-1P>D*MEOHIJRB_G
M=Q>BOH]D?B7&6#^O8:.(IJ]?!N<[)>].A.WM(JV_(XJI'R4TES2U^RJ**.O2
MOHS\K.\^&7PX\5?%OQUX;^'G@K3WU+Q'XHU*+3K" $I%$&#27-[>3;6%O8:?
M:1SWVH73*RVME;W%PZE(FK^M[]FW]GKP?^S9\,M*\ ^%XHKB^*QW_BSQ&8%B
MO?$_B*2%$N]1N#EY([2''V72;%I)%L+"..,O-<R75U<?#G_!+G]F"+X=?#P_
M'+Q7IRKXU^)-B%\+I<Q*9M#\!N\<L%Q"3DQW'BN:*/46D4MNT6#2#$T7VR^B
M?]8:_@SZ0'B94XDSJKPEE.(?]@9%B'3QLZ4GR9IG%%N%:4VG:>%R^?-A\/'X
M)XB-?$WJ1>&E3_U$^BKX-4>#^'*/'F?81/BGB;"1JY="O!>TR3A_$*-3#PIQ
MDKTL;FT.3%XN=U4IX26%P?+2FL9&L4445_.1_7@4444 %%%% 'X_?\%"_P#@
MD[\-OVK=.UOXC?"F#2/AI^T$L,MX=1A@%EX2^(]U&FX67C.TM(B+/6+K:(H/
M&%E;R7H=@NMVNKP);/8?S1_ WX(?$#X/?$+XJ:'\4_"FJ>#O&/A.YM/!MYHN
ML6_DW4%R6&JWDUO*I>WO+"ZMQI5S8ZC8S7&GZC:7$%Y8W-Q:S13/_>Z2 "2<
M <DGH!ZFOYC?VP/B!!\9OCAXW\2V4Z3:797O_"/^&;A-C1R:+H2C3[6:.1"2
M]MJDL,^KH&):)]1=<#!2OXC^F3F/#O"'!.$E2Y<'G7&><4LK=&ARQC6P.$2S
M#,\QG25FO8SI8'!XBI25ZCS*#J1G)N1^(\<^&^05,YP/%F7THX'-X5J\L3A:
M$(1PF9RG0JP>)J4URJCC*4ZD9NO326(FU]8A*I)5X_'-%/D1XG:-U*NA*LIZ
M@C_.0>A'(X-,K_-I--)IIII--.Z:>J::T::U36Y\<TTVFFFFTTU9IK1IIZII
MZ-/8****8C]H_P#@DOXKD:W^+_@F9QY4;^&?$]A'N_Y:/_:>F:O)M]2O]BH6
M[A54]!7[*U_/W_P2NU:2U^/WB?2\GR=5^&.MY'8S6?B'PK<1G_>$:S8[@;L<
M$U_0)7^M_P!$_,ZF8^"N04:DG.64YCGN6)MW?LXYI7QU*+;UM"ECH0BND(Q2
MT2/W/@BLZO#V%BW=T*N)HW\E6E5BODJJ2\D@HHHK^D3ZT**** /\X;_@I3_R
M?Q^UQ_V7?XA_^I#>5\05]O\ _!2G_D_C]KC_ ++O\0__ %(;ROB"O[ER3_D2
MY/\ ]BK+O_4.B?P9GO\ R/,Y_P"QKF/_ *EUC_4T\&_\BAX5_P"Q;T/_ --=
MK7^=C_P4R_Y/\_:V_P"RX>.O_3O/7^B=X-_Y%#PK_P!BWH?_ *:[6OS7^+'_
M  1N_84^-?Q)\:_%CQ_X#\7ZCXT^('B'4O%'B:^L_B+XJTZUNM7U:X>ZO)K>
MPM;U+:TB>5V,=O BQ1+A(U50 /YA\/>*LLX4S7-,5F<,7.EBL)]6IK"4J=6:
MJ+%4ZK<XU*U!*/+!ZJ3=[*Q_4_B+PEFG%V3Y3A,KG@Z=7"XN.)JO&5:M&#IO
M"5*/N.E0KMRYIIV<4K7UOH?Y^=%?WE?\.'O^"<O_ $3;QQ_X=+QE_P#)]'_#
MA[_@G+_T3;QQ_P"'2\9?_)]?K?\ Q&/A+_GQG?\ X187_P">']6?E?\ (/\
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M?]BG\5O_ %7'B2O')/\ @D1_P4<:1V'[+7C3#.Q'_$Y\$="Q(_YFCTK],?\
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M32Y%CDBE2Y:1VE&\.H .T\?H1_Q$I?&__HV_X5?^%)XN_P#CU?F5_P .A_\
M@H[_ -&M>-/_  =>"/\ YJ*/^'0__!1W_HUKQI_X.O!'_P U%?0YAEOAIFF,
MK8_,*W#N)QF(<95J\\[IPE4<*<*46XT\PA!6IPA'W8K2-WK=GSF79IXH95@Z
M&7Y=0XCPV#PRE&A0AD524:<9U'5DE*IE\YOFG4E)\TF[S:VT7U=\=O\ @O\
M?MG?%GPOJGA'P3I?PZ^"-EK%G/8WGB#P+IVMWGCB.VN5\J9--\0^(=;U*UT>
M5X6=$U#2M&L]7M'99[#4K2XC24?AI//-<S2W-S+)/<3R/-//,[22S2R,7DEE
MD<EWD=R6=V)9F))))K]++#_@CM_P4CU&:.&']E_Q-"78+YE]XL^&^G0IG/S/
M+?\ C.V55R.3DXR#T.:^U/@9_P &[_[6?C;5+&X^-OBWX??!3PQYL+:E%;:F
MGQ#\:>1O5IHK#2?#LL?AAI6B#(LUUXQ@$,C!S;SJAC?IPN:^'_"V%JK 9AD&
M HSM4JPP6*HXK$5G!/E<XX>IB<9B'%2:@FJG+S244KLY<5E'B+Q9BJ,LPR[B
M#'UH+DHSQV%K83#4%-QYN26(AAL'AU.T74<?9\_*G*[BK?EE^P]^ROXN_;$_
M:0^'GP:\-6%Y)I.HZQ:ZK\0-;@CD^S^%?A[I=U!-XIUZ[N%4QV\D=@QL=)69
MXUOM>OM*TQ)%FOHJ_P!$?_A17PC_ .A#T#_P%_\ LJ\8_8Y_8=^ O[#_ ( ?
MP5\&_#\W]IZLMI+XS\?Z^UO?>-O&]]9HZP3ZUJ<%M:PP6%HTLYTW0M+MK+1]
M.\^>:*T>^NKZ]N_L"OP3C[C>7%&9T7E[KX;+,OA5I83FE*E6KSK2@Z^)JQA-
MJ"J>RI0ITVVX4Z:E*TZDX1_H/P^X%APIE=99@J&)S3,*E*MC'&*JT</"C&2H
M86E*<5S^R=2K.I548J=2HXQ3A"$I?YX__!>+X42_"S_@IC\7]22!K?2OBSH7
M@/XK:/E-B2IJ_ANS\.Z[,C8"MYOB[PMXCD=@2V]CN()Q7Y;Z+,/E&>PZ>W/Y
M9]?Q[5_63_P<]?L]3ZGX(_9Z_:ET>Q:1_!^M:O\ !SQO<PQ!W32/$\<OBGP3
M=7+@;HK+3M6TKQ99&1B8_MGB2SA.'F0-_(SH]T!MYY&!_AT/X8_IQ7]<^%6<
M0SG@?AZOS*53"X.&5XA7O*-;*W]47/\ WJE"G1KZZN-6+ZG\5^,>12R7CWB/
M#\CC2Q>-EFN&=K1G1S1+&MT]-8T\15KX?MS49QZ'N^BW ^7D<@>O^>OX]._!
M]8T:Z *'/H.OZ8/3M_\ JXKP32+P#;\W'!'YXP.?R],#UKT_2K\#;\W89]OP
MZ\<?D.E?JE&>WRT\[JS^[[_N/PS'4&[_ (_AOVWVT7F?0&DWH4*<],9]Q^GI
M[<$XZ"OO7X4^+?%GPLN_"WBGP3KFH^&O$^A);7]EJNF3M!<P74B&68-PT<\$
MPFE@NK2XCFM;NVDEM;J&:VFEB?\ -[PY=&[U#3;+.3=WMG:@#//VBXCA_/#\
M_I7Z';0GR+]U,*O^ZORC] *]K#4J6*I8BC7I4Z]"K2=&M1K0C5I5:56,H5*5
M2G-2A.G.%XSA).,HR:<7%V/SW/:V(P&(P-;"UJN&Q-&M]:P^)P]2=&O0K8>5
M.5"M1K4W&I2JTZCYZ<X24Z<XQE%J2N?TI_LC?\%)O OQB@TSP1\7[C3/ 'Q,
M*6]I;ZK-(MGX/\87)VQ*UI=3N8]!U>X<KNTR^E6QNIG4:9>&:=-+M_U%!!&0
M<@\@CH1ZU_#0"5(*D@CD$$@@^H(Y%?H'^S;_ ,%%?C7\!H[#PYK-Q_PLSX>V
MGEPQ^&_$MY/_ &GI5HK?ZKP[XC*W-[IT<:82"QO(M3TFWB01VNG6[,91_+OB
M+]&Z&)J5\WX J4L/4FY5:W#>+JJGAW-ZM95C*CY:"D]5@\9)4(-R]GBZ-)4\
M/'^QO"+Z8$\)1PN0^*E.OBJ=-0H8?B_ T/:XJ,%:,7GF7T4IXEQC?GQ^7PEB
M9I1]K@,16E5Q4OZE**^+/@C^WU^SC\;8[.SL_&$'@?Q5<B.-O"GCR2WT*[>Y
M<'$&FZM+,VA:JTC*XMX+74!J,J /)IT!8)7VBCI(JNC*Z.JNCHP971@"K*P)
M#*P(*L"0000<5_)N<Y!G?#N+E@,\RO'95BXM_N<;AZE!S2=N>C.<53KTGO&M
M1G4I333C-IIG]V\.\4\.<6X"&:<,YWEN>8&:7^T9=BZ6)5.4E?V6(A"3JX:N
ME\=#$0I5H.ZG3BTT.HHIKND:-)(RHB*SN[L%1$4%F9F8@*J@$LQ(  ))P*\A
MM)-MV2U;>R7=GO#J_%_]O/\ :QB\337?P5^'&J"7P_8W03QQKUA,&BUO4+24
M,N@V5Q$Q632M-N8UDO9T8K?ZC#&D16SLEEU'J/VR?VX898-3^%/P6U;S$G6:
MQ\6>.]/FPLD3 QW&C>%[F-LF*52T5]KD3#SHB\.E,89!?O\ D02222<DG)/O
M7^9'TM/I187,L-F/A7X;YC'$82M[3!\8\3X*JI4,323<*_#N48BF^6MAZC3I
MYQCJ4G2Q%/FR[#SJ4*F+E+X[/<ZC*,\#@YJ47>.(K1>C6SI4Y+=/:I):->XF
MTY"4445_F\?(!6?J=M]IM)% S)&/,CZ9W*#E><?>7(^I%:%%:T*T\/6I5Z;M
M.E.,UV=GJGY25XM=4VB*E.-6G.G-7C.+BUY-6OZK=/H[,\WHJW?P_9[N>(?=
M#EEXP K@.H ] &Q^%55!9@HQEB ,D 9)P,D\ >I/ K]0IU(U:=.K#6-2$*D7
M_=G%2C^#1\+4A*G.=.7Q0E*$O6+:?XH_=#_@D_X,:P\ _$_QY+ R-XB\2Z1X
M:MI)%(WP>&=.GU&=X2?O122>)X8V8=9;5EZIQ^L]?.7[)?PU?X4_L^?#7PI<
MP-;ZJ^AIK^NQ2#$\>L>)99-;N[6X) )ETU;V+2LXX2P11PHKZ-K_ &T\%^&*
MG!_A9P1D%>FZ.+PV1X?%XZDU:5',,VG4S?'T9]7*AB\=6HMO_GWII8_H3A_!
MO 9+EV&DG&<,-"=6+T<:M=NO4B_.,ZDH_(****_3SV0HHHH **_EAU#]E_PK
M^VC_ ,%FOVV/A'\3_'OQ:\-^$/"7@+PSXWT>'X<>,D\/7,>KVWACX)Z.L+_V
MCI6NV0L)+?Q#J$TL$%C#(UUY4HG4"5)?NMO^"$7[+>UO)^-?[7,$N#Y<R?%O
MPZ7B?LZAOA[@E3S@\5]IBN',BR^."AF/$F(P^)Q>6Y?F3HT<BGB84H9AA:6*
MIT_;+,J?M'"-3EE)4XW<;\JO9?$83B3/\QECIY;PUA<1AL%F>8Y8JU;/XX:I
M5J9=BJF%J5/8O*ZO(IN'/&+J2LFES.US]LZ*_GB_8_M_BS^Q7_P5$UO]A:\^
M.7Q&^,WP*^(7P6G^(W@>S^)NLSZ[K'A;4[6TDU&WEMYY9#:6%Q"/#?BG2KV/
M1+72]-UBUN]-OKK38[RSA,7VO_P6=U"_TK_@F_\ M"7^EWUYIM];GX8F"\L+
MJ>SNH2_Q=\"1N([BVDCE021N\4BJX62)WC<,CLIY*_#/LL]R7**>/IXC#9[_
M &54P.8PP]2">%S6M&A3K5,+4E"<*E*?M%4HNIJX651*5UV4.)_:Y#G>;U<O
MJ8?$Y!_:M+'Y=/$4YM8K*J#Q%2C3Q=.$J<Z=:FZ;IUU2VJ7=*\6G^HU%?)'[
M UQ<7?[$7[)-U=W%Q=W5Q^SM\(IKBZNIY;FYN)I/ ^BO)-<7$[R3332.2\DL
MKO([$LS$DFOR#\.Z3\2?^"L_[7W[6_@[Q=\>OBW\)OV5/V6O%]E\,?#_ ,/?
M@]KL7A*?QYKJ:KXHT2^UKQ)JLEO?P:F+NY\(:SJC?VGI>H_9++5-&T_2TL#:
MW=U>XX+A]8C$YQ'$8ZG@\OR+G>.Q\Z%2M*WUR.!H0H86E+FJU\37G%4Z;JPA
M&*G*=:*A=[8WB%X;"Y++#8"IC<QS[D6 R^&(IT8W^I2Q^(G7Q=6/)2H8:A"3
MJ5%2G.4G",*,G.R_HL-U;"3RC<0"7./+,L8DSZ;-V[/MC-3U^*Y_X(,?L0,I
M8ZS^T";X_,=4/Q4@.H>;_P ]]Y\+FW,H/S FV*Y_AQQ7S7J?P\^)G_!*']LC
M]D?1/ W[07Q7^)?[*?[4'CR;X2>)?AW\6=?'B/\ X0_Q!J%YHVCZ5J&G7$<-
MEIEJ8KSQ/I6JV.H:1H^DW[P:'JNE:HU]:7B-790R#)<Q=7#Y-G]?%9A##8G$
M4<)C<FE@(8M83#U,55HT,12Q^.C&NZ5*HZ4:U.G"I**A[2+DCBQ'$.>98J6(
MSKAVAALNGBL+AJ^,P&=0S">$^N8BEA:-:OAJN7X"4J$:U:FJLJ,ZLZ<&Y^SD
MDT?T>45\L_MQSSVO[&/[5]S:SSVMS;_LZ?&6:WN;::2WN;>:+X?:^\4T$\+)
M+#-&X#QRQ.LB. R,& -?@G_P3D_X)7?!+]K#]C_X6?'CXE_%K]I2P\9^-)_&
M\>K6OA/XFZ9IF@Q+X=\>^)?#-A]BLM2\(ZS>0E]/TBU>Y\[49]]TTTD8BC9(
MDY\KR+ 8K*,3G.99M4RW#X?,:&6QC1RV683J5L1AJV)C)VQF%Y(J%"HGI+6V
MJN=6:Y]F&$SC"Y+EF44LSQ.(R[$9G*=;,UE].E1P^)H8644W@\7[2;GB(-?#
MI?L?U)45^%_B7_@AK\*]&T/5M4^#'[3O[6W@+XC66G7EQX3UZ?XH:;>V-MK<
M-M*^F_VA!I'A?P[JSV378B%Q_9^MZ?=+$6,,ZL #[W_P1V_:>^(G[4/[']MK
M/Q;UB?Q%\2/AC\0?$WPH\2^)+W8=4\0KH=CH>N:/JFKR1JJ7&J+I'B.TTJ]O
MB#/J4^EOJ-X\M[=W$TBQN18&.5U\VRC./[4P^"Q.%PV.I5LOJY=B,.\;&N\-
M5C"5?$TZU&I+#5:<I1JQG"?)>GRRNC!9]CY9IA\HSC)UE>(QN%Q6*P-6AF-+
M,<-B%@I8=8JC*<:&%JT:U..)I5(QE1E"=/G:J*4>5_JK17X'>*M9UA?^#@3X
M:Z(NJZDNC/\ LTW]R^DK?70TU[@>#/'Y$SV(E%L\@9$<,T1(=$D^^JL/WQKA
MS?*7E2RINNJ_]J9/A,V5J?L_8K%3KP5!^_/VCA["_M/<YN:W)&UWWY/FZS9Y
MLEAW0_LO.<9E#O5]I[=X2%";Q"_=P]FJGM[>R]_EY;^TE>R**_$?_@OUJ^JZ
M+^PGI][H^IZAI-Y_PO3X?1?:M-O+BQN#%)H?C;?$TMM)$[1.55FC9BA9$8KN
M12/V ^&+O)\-OA[)([22/X'\)N[NS.[NV@:>S.[L2S,S$EF8EF))))-&(RET
M,DRW.?;J2S'&YC@UA_9<KHO+X8.;J.K[1\_M?KB2C[.')[-OFES>Z8?-UB,]
MS/)?J[@\NP.6XUXGVJDJRS">,@J:I>S3A[+ZI=S]I/G]I;EARWEW%%<QXV\8
M:#\/?!OBSQ[XJO4TWPSX)\-:YXL\0ZA)C99:)X=TRYU?5+HY*@^196D\@7(W
M%0H.2*_BF\->+/VB/#<'A7_@LOJWB+Q=-X>UO]MW6=.UOX?I?W=SI*?"S4O-
M^W/:QK,L"Z/(S^)?A9:KM:&TNK33@B^:ZFO4X:X5J<14\;46-IX%4)4,+@_:
MTG46/S3%PKU,)EU.2J4U3G6CAJCE5?M/9WA>G+G1Y7$_%E/ANI@:;P-3'O$1
MKXO&>RK*F\ORK"5,/3Q>8U(NG4=2%&6*I\M+]W[2T[5(\C/[@**RM"UO2O$V
MB:-XDT*^@U/0_$&E:?K>C:E:N)+;4-*U6TAO].OK>0</!=V=Q#/"XX:.16'6
MO/?CS))#\#?C-+#))#+%\*/B+)%+$[1RQ2)X0UADDCD0J\<B, R.C!E8!E((
M!KYBG2<ZU.B[PE.K&D[IW@Y34'>+L[Q;U3L]+:'U-2K&%&=>-IQA2E57+)6G
M&,'-6DKJTDM)*ZL[ZGJ]%?R=_P#!+W_@F?\ "#]LO]EJS^-/Q6^*_P"T9IWB
MVZ\?>,?#<EMX,^).GZ3H@T_0I-/%DZ6FJ>%==NQ<L+N7SY#?F-\)LACVG=^A
M=U_P0I_9YMX))_"?[0_[7WA;Q!$I?2]=@^*F@W3Z?=J,PSFWB\$:?-,D<@5G
MCAOK.9U!6.YA8B1?LLRX<X<RK,,9EF*XIQ,<3@L14PM?EX=JSI*K2ER3:G',
MVY033]Z,&VEI%MV/BLMXDXFS7+\'F>$X4PDL+CL/3Q5!2XDIPK.E5BIPO"65
M*,9M/X95$D]')+5?MS17XM?\$@OCO\:?$L_[5W[*OQZ\;ZE\3?&?[(GQ9_X0
M?2?B#KLL]UKVO^&+K5/%N@00:GJ%U-<WVI"RU'P3>7UC>:I=7FI"QUN'3Y[N
M:'3K8)\B_P#!;3P+XI^,'[7O["WP3\,>,-8\(7?Q4TGQQX4L[[3M2O+*WCUG
M4M<T:UT6>^2VE19+9-1DMTN7*M(EJTI0A@N,,+PE*KQ-5X=Q68T<-"EAZ^,E
MF5.A4Q%&6$IY:\TI5X47.A4<:V%Y)<KDI4W-IJ3C9[8KC&%+A:EQ)A,MK8F=
M7$X?!1RRI7AAJT<95S..4U</.O&&(IJ5#%N<>=1E&HH)IQ4KQ_I?HK\>_P#@
MBM^T;KGQB_93F^$_Q#N+T?%[]E_Q1??"/QI8ZO([:ZNBVL]W+X,N]3CEEEFC
MDM+2WU/P:WFL97N?!MS+)\\A)_82O!SC*Z^2YICLKQ#4JN"Q$Z/M(JT*U/25
M'$05W:GB*,J=:GJ_<J1U/H<ES2AG>58#-<.G"ECL/"M[.3O.C4=XUL/4=E^\
MP]:-2A4T7[RG+1!17\8'_!3WXC^//VM?CQ^V7\3O!/B_7]*^"?["7@WP+\--
M-GT+5[RSTW7/'_B'XJ:)X,U-'6U=+>>XO]=U;QW.+Z*1S<:)X&T<!MDJ5_4I
M^PK<7%W^Q9^R;=7=Q/=W5Q^SK\')[BZNII+BYN)I? .@O+-//,SRS32.2\DL
MKL[N2S,6)->[G?"=3),FRS-*V.A5Q&.J0I8G 1H.$\!5JX&AF-.E5K.K+VE1
MX7%8><X*E3Y'4Y6VXN_@Y%Q=3SS.LTRNC@9TL/@:=2MA<Q>(52&84J6.KY;5
MJTJ*HQ]G26+PN)IPG[:I[2-+FM'FLOJNBH+JZMK&VN+V\GBM;2T@FNKJYN)%
MB@M[:WC:6>>:5R$CBAB1I))'(5$5F8@ FOXD/B=XB_:#^/6K?M/_ /!6KX>>
M+_%-IX1^!?[57PULOASX;BO]4CT74? GAJ]@L+>ZNK.*1%6#1[)OA(FLVMM
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MHQ>, +FX_:OU>*8D8<K!JGC65 Q/S8#W4V W0ENY-?IE_P $_O\ DQK]D/\
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M?BQLJH077Q.MU\1W)4(66>>/(5S7XW_M-W_[17[:7_!6YX?V6_#WPW\;Q_L
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M>"5_&.FV4]M_I0>Z\*M?ZG:V]MF6XUW0]#V#S(HR/R1\;_M&2_\ !7WXH_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
